The drug, odanacatib, limits risk of osteoporotic fractures. However, a late-stage study found postmenopausal women were at an increased risk of stroke when taking the drug. Merck said Friday the findings do not support additional development or regulatory approval.
More articles about supply chain:
Mylan coupled executive pay with high profit targets: 7 things to know
Sunovion Pharmaceuticals to acquire Cynapsus Therapeutics for $624M
Roche seeks FDA approval for additional use of cancer drug
Register to Attend Webinar
Presenters:
James Germano, MD, Joint Reconstruction Specialist|Tim Tzimas, Innovative Sterilization Technologies
Next Up in Supply Chain
-
Medical device makers have faced several cyberattacks in 2026, disrupting manufacturing, shipping and order processing for hospitals nationwide. Here’s where…
-
As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…
-
Ville Platte, La.-based Mercy Regional Medical Center has signed a prime vendor agreement with Medline for medical-surgical products and distribution…
Join the 500,000+ healthcare executives who start their day with Becker's
Becker's Hospital Review Newsletter is sent Monday–Sunday.
